To view Article Recommendations, you must have an active subscription.
If your access has expired, you can subscribe at $9.95 per month.
If you think you should be able to access this content, please contact us.
New to F1000? See this week’s top article below for a free preview of a Recommendation.
HEADS OF FACULTY
These last 15 years have led to the approval of three drugs (imatinib, sunitinib, and regorafenib) for the treatment of advanced gastrointestinal stromal tumors (GISTs), which have significantly improved survival. However, nearly all patients with...
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
2 Recommendations, most recent by| New Finding
Past 7 Days
New Articles Recommended
Past 30 Days
7Articles Classified As Interesting Hypothesis1,407 total
10Articles Classified As Confirmation2,265 total
7Articles Classified As Review / Commentary548 total
7Articles Classified As Novel Drug Target718 total
9Articles Classified As Technical Advance744 total
3Articles Classified As Controversial690 total
54Articles Classified As New Finding5,988 total
9Articles Classified As Good for Teaching879 total
Get instant access to Article Recommendations from more than 8,000 leading experts in Biology and Medicine by taking out a monthly subscription.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
Your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.